Data from an observational study of outcomes for patients with cancer who were also diagnosed with coronavirus disease 2019 (COVID‐19) indicate a racial disparity in gaining access to the drug remdesivir as well as increased mortality associated with the steroid dexamethasone. The data form the basis of the second report on 2186 patients in the United States by the COVID‐19 and Cancer Consortium (CCC19), which has been published in Cancer Discovery.1 Consortium researchers also confirm in the report that unproven COVID‐19 therapies were broadly used outside clinical trials.
RECOVERY Trial Findings
According to the United Kingdom’s RECOVERY trial assessing the efficacy of different treatments for hospitalized patients with COVID‐19 using the end point of mortality within 28 days, which has been published in The New England Journal of Medicine, dexamethasone lowered the death rate in critically ill patients. CCC19 data, however, revealed the drug’s association with increased mortality among patients diagnosed with cancer and COVID‐19. The latter study showed that patients who received high‐dose corticosteroids with any other potential COVID‐19 treatment were twice as likely to...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).